Vanillylmandelic Acid

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 204 Experts worldwide ranked by ideXlab platform

Cindy Laukes - One of the best experts on this subject based on the ideXlab platform.

Philippe J Eugster - One of the best experts on this subject based on the ideXlab platform.

Michael J. Garvey - One of the best experts on this subject based on the ideXlab platform.

J Zieschang - One of the best experts on this subject based on the ideXlab platform.

  • Serum Vanillylmandelic Acid/homovanillic Acid contributes to prognosis estimation in patients with localised but not with metastatic neuroblastoma.
    European Journal of Cancer, 1992
    Co-Authors: Frank Berthold, D.h. Hunneman, Dieter Harms, H Käser, J Zieschang
    Abstract:

    Abstract In 211 patients with neuroblastoma, serum Vanillylmandelic Acid (VMA) and homovanillic Acid (HVA) levels were determined and correlated to stage, histological differentiation, ferritin, neuron-specific enolase, lactate dehydrogenase (LDH) and outcome. Elevated serum VMA and/or HVA levels were found 16% less frequently than elevated urine levels. The incidence of the elevated serum levels increased with stage (stages I–III 58%, IV 78%, IVS 100%). Increased VMAHVA ratios were not associated with a higher grade of tumour differentiation. Serum ferritin and neuron-specific enolase showed no correlation, and LDH a borderline non-random correlation with the serum catecholamine metabolites. Using age-related reference values a quotient of serum VMAHVA ( P = 0.061) P = 0.0004). No correlation with prognosis was detected for patients with stage IV and stage IVS disease. We conclude that serum VMA and HVA determinations may be useful as tumour markers for 71% of neuroblastoma patients, and aid in estimating the prognosis in children with localised disease.

  • Serum Vanillylmandelic Acid/homovanillic Acid contributes to prognosis estimation in patients with localised but not with metastatic neuroblastoma.
    European journal of cancer (Oxford England : 1990), 1992
    Co-Authors: Frank Berthold, D.h. Hunneman, Dieter Harms, H Käser, J Zieschang
    Abstract:

    In 211 patients with neuroblastoma, serum Vanillylmandelic Acid (VMA) and homovanillic Acid (HVA) levels were determined and correlated to stage, histological differentiation, ferritin, neuron-specific enolase, lactate dehydrogenase (LDH) and outcome. Elevated serum VMA and/or HVA levels were found 16% less frequently than elevated urine levels. The incidence of the elevated serum levels increased with stage (stages I-III 58%, IV 78%, IVS 100%). Increased VMA/HVA ratios were not associated with a higher grade of tumour differentiation. Serum ferritin and neuron-specific enolase showed no correlation, and LDH a borderline non-random correlation with the serum catecholamine metabolites. Using age-related reference values a quotient of serum VMA/HVA (P = 0.061) < 0.7 indicated a poorer event-free survival (48 +/- 10%) than ratios > or = 0.7 (event-free survival 81 +/- 6%) for children with localised neuroblastoma (P = 0.0004). No correlation with prognosis was detected for patients with stage IV and stage IVS disease. We conclude that serum VMA and HVA determinations may be useful as tumour markers for 71% of neuroblastoma patients, and aid in estimating the prognosis in children with localised disease.

  • serum Vanillylmandelic Acid homovanillic Acid contributes to prognosis estimation in patients with localised but not with metastatic neuroblastoma
    European Journal of Cancer, 1992
    Co-Authors: Frank Berthold, D.h. Hunneman, Dieter Harms, H Käser, J Zieschang
    Abstract:

    In 211 patients with neuroblastoma, serum Vanillylmandelic Acid (VMA) and homovanillic Acid (HVA) levels were determined and correlated to stage, histological differentiation, ferritin, neuron-specific enolase, lactate dehydrogenase (LDH) and outcome. Elevated serum VMA and/or HVA levels were found 16% less frequently than elevated urine levels. The incidence of the elevated serum levels increased with stage (stages I-III 58%, IV 78%, IVS 100%). Increased VMA/HVA ratios were not associated with a higher grade of tumour differentiation. Serum ferritin and neuron-specific enolase showed no correlation, and LDH a borderline non-random correlation with the serum catecholamine metabolites. Using age-related reference values a quotient of serum VMA/HVA (P = 0.061) or = 0.7 (event-free survival 81 +/- 6%) for children with localised neuroblastoma (P = 0.0004). No correlation with prognosis was detected for patients with stage IV and stage IVS disease. We conclude that serum VMA and HVA determinations may be useful as tumour markers for 71% of neuroblastoma patients, and aid in estimating the prognosis in children with localised disease.

Piero Rinaldo - One of the best experts on this subject based on the ideXlab platform.

  • Liquid Chromatography–Tandem Mass Spectrometry Method for the Determination of Vanillylmandelic Acid in Urine
    Clinical chemistry, 2003
    Co-Authors: Mark J. Magera, Abby L. Thompson, Dietrich Matern, Piero Rinaldo
    Abstract:

    The biochemical detection of catecholamine-secreting tumors relies on the determination of several metabolites, among them Vanillylmandelic Acid (VMA), a metabolite derived from epinephrine and norepinephrine via the intermediate 4-hydroxy-3-methoxyphenylglycol (1)(2). VMA may also be produced by the oxidative deamination of normetanephrine and metanephrine or by O-methylation of dihydroxymandelic Acid, a minor metabolite of norepinephrine (2)(3). Our laboratory is actively involved in the application of stable-isotope-labeled internal standards and tandem mass spectrometry (MS/MS) to the determination of a wide variety of biochemical markers currently being tested with more conventional analytical platforms. This effort has substantially improved the efficiency and effectiveness of our services and reduced turnaround time in a high-volume testing environment. The following is a report of our development of a MS/MS method for the determination of VMA in urine. VMA was purchased from Sigma, and d,l-Vanillylmandelic Acid, ring-2H3 98% (d3-VMA; GC/MS for isotopic enrichment 99.7%) was purchased from Cambridge Isotope Laboratories. OasisTM HLB solid-phase extraction columns were obtained from Waters. All other chemicals and solvents were of the highest purity available from commercial sources and were used without further purification. Stock solutions of VMA and d3-VMA were prepared by dissolving 5 or 10 mg, respectively, in 10 mL of 0.1 mol/L HCl. A working solution of VMA (20 mg/L) was prepared by diluting stock solutions with 0.1 mol/L HCl. Calibrators were prepared in deionized water by the addition of working solution (20 mg/L) to VMA concentrations of 0 (blank), 1.04, 2.08, 4.17, 8.33, 12.50, 16.67, and 20.00 mg/L. Prepared calibrators were then treated as specimens …

  • liquid chromatography tandem mass spectrometry method for the determination of Vanillylmandelic Acid in urine
    Clinical Chemistry, 2003
    Co-Authors: Mark J. Magera, Abby L. Thompson, Dietrich Matern, Piero Rinaldo
    Abstract:

    The biochemical detection of catecholamine-secreting tumors relies on the determination of several metabolites, among them Vanillylmandelic Acid (VMA), a metabolite derived from epinephrine and norepinephrine via the intermediate 4-hydroxy-3-methoxyphenylglycol (1)(2). VMA may also be produced by the oxidative deamination of normetanephrine and metanephrine or by O-methylation of dihydroxymandelic Acid, a minor metabolite of norepinephrine (2)(3). Our laboratory is actively involved in the application of stable-isotope-labeled internal standards and tandem mass spectrometry (MS/MS) to the determination of a wide variety of biochemical markers currently being tested with more conventional analytical platforms. This effort has substantially improved the efficiency and effectiveness of our services and reduced turnaround time in a high-volume testing environment. The following is a report of our development of a MS/MS method for the determination of VMA in urine. VMA was purchased from Sigma, and d,l-Vanillylmandelic Acid, ring-2H3 98% (d3-VMA; GC/MS for isotopic enrichment 99.7%) was purchased from Cambridge Isotope Laboratories. OasisTM HLB solid-phase extraction columns were obtained from Waters. All other chemicals and solvents were of the highest purity available from commercial sources and were used without further purification. Stock solutions of VMA and d3-VMA were prepared by dissolving 5 or 10 mg, respectively, in 10 mL of 0.1 mol/L HCl. A working solution of VMA (20 mg/L) was prepared by diluting stock solutions with 0.1 mol/L HCl. Calibrators were prepared in deionized water by the addition of working solution (20 mg/L) to VMA concentrations of 0 (blank), 1.04, 2.08, 4.17, 8.33, 12.50, 16.67, and 20.00 mg/L. Prepared calibrators were then treated as specimens …

Related terms

Vanillylmandelic Acid - 15 days free trial to Access Experts & Abstracts